MRKR
Marker Therapeutics, Inc.NASDAQHealthcare$1.32+6.82%ClosedMarket Cap: $14.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
4.29
EV/EBITDA
1973065.38
DCF Value
$1,049,507.82
FCF Yield
-78911210.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-137.3%
Operating Margin
-363.5%
Net Margin
-343.0%
ROE
-0.0%
ROA
-0.0%
ROIC
-0.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.1M | 0.0% | $-1.9M | $-1.7M | $-0.10 | — |
| FY 2025 | $3.5M | 0.0% | $-12.4M | $-12.2M | $-0.79 | — |
| Q3 2025 | $1.2M | 100.0% | $-2.1M | $-2.0M | $-0.12 | — |
| Q2 2025 | $861.2K | -385.0% | $-4.3M | $-4.0M | $-0.29 | — |
| Q1 2025 | $349.1K | -798.1% | $-4.6M | $-4.4M | $-0.40 | — |
| Q4 2024 | $2.3M | -125.9% | $-3.9M | $-3.8M | $-0.42 | — |
| FY 2024 | $6.6M | -104.3% | $-11.1M | $-10.7M | $-1.19 | — |
| Q3 2024 | $1.9M | -80.2% | $-2.4M | $-2.3M | $-0.26 | — |
| Q2 2024 | $1.2M | -99.7% | $-2.3M | $-2.2M | $-0.25 | — |
| Q1 2024 | $1.2M | -107.0% | $-2.5M | $-2.4M | $-0.27 | — |
| Q4 2023 | $1.1M | -147.7% | $-2.9M | $-2.8M | $-0.31 | — |
| FY 2023 | $3.3M | -214.6% | $-14.6M | $-8.2M | $-1.93 | — |